###BASE_URL###
2010-04-15 | permalink
Dutch biotech firm Pharming clinched on Thursday a European distribution deal and an upfront payment for its drug Rhucin with Sweden’s Orphan Biovitrum as it prepares for its first product launch. Pharming is waiting for the European Medicines Agency (EMA) to approve the marketing of its lead product Rhucin after previous attempts were turned down. It expects EMA to issue its final opinion in the third quarter of this year.
2010-04-15 | permalink
Dutch biotech firm Pharming clinched on Thursday a European distribution deal and an upfront payment for its drug Rhucin with Sweden’s Orphan Biovitrum as it prepares for its first product launch. Pharming is waiting for the European Medicines Agency (EMA) to approve the marketing of its lead product Rhucin after previous attempts were turned down. It expects EMA to issue its final opinion in the third quarter of this year.